Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Amifampridine Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,404Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Zenas, 3,4-diaminopyridine phosphate, 446254-47-3, Firdapse (tn), Amifampridine phosphate [mi], 3,4-pyridinediamine, phosphate (1:1)
    Molecular Formula
    C5H10N3O4P
    Molecular Weight
    207.12  g/mol
    InChI Key
    KAICRBBQCRKMPO-UHFFFAOYSA-N
    FDA UNII
    8HF8FIN815
    4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    phosphoric acid;pyridine-3,4-diamine
    2.1.2 InChI
    InChI=1S/C5H7N3.H3O4P/c6-4-1-2-8-3-5(4)7;1-5(2,3)4/h1-3H,7H2,(H2,6,8);(H3,1,2,3,4)
    2.1.3 InChI Key
    KAICRBBQCRKMPO-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1=CN=CC(=C1N)N.OP(=O)(O)O
    2.2 Other Identifiers
    2.2.1 UNII
    8HF8FIN815
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3,4 Diaminopyridine

    2. 3,4-diaminopyridine

    3. Amifampridine

    4. Firdapse

    5. Ruzurgi

    2.3.2 Depositor-Supplied Synonyms

    1. Zenas

    2. 3,4-diaminopyridine Phosphate

    3. 446254-47-3

    4. Firdapse (tn)

    5. Amifampridine Phosphate [mi]

    6. 3,4-pyridinediamine, Phosphate (1:1)

    7. Amifampridine Phosphate [usan]

    8. Amifampridine Phosphate [mart.]

    9. Amifampridine Phosphate [who-dd]

    10. 446254-47-3 (phosphate)

    11. Amifampridine (phosphate)

    12. Amifampridine Phosphate [ema Epar]

    13. 3,4-dapp

    14. 8hf8fin815

    15. Pyridine-3,4-diamine Phosphate

    16. Amifampridine Phosphate (usan)

    17. Unii-8hf8fin815

    18. Phosphoric Acid;pyridine-3,4-diamine

    19. Starbld0005260

    20. Schembl3958357

    21. Chembl3301611

    22. Dtxsid40196254

    23. Hy-14946a

    24. Amifampridine Phosphate [orange Book]

    25. Cs-0009524

    26. 3,4-diaminopyridin-1-ium Dihydrogen Phosphate

    27. D10689

    28. Q27270515

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 207.12 g/mol
    Molecular Formula C5H10N3O4P
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count0
    Exact Mass207.04089281 g/mol
    Monoisotopic Mass207.04089281 g/mol
    Topological Polar Surface Area143 Ų
    Heavy Atom Count13
    Formal Charge0
    Complexity124
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Neuromuscular Agents

    Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS. (See all compounds classified as Neuromuscular Agents.)

    Potassium Channel Blockers

    A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. (See all compounds classified as Potassium Channel Blockers.)

    4.2 FDA Pharmacological Classification
    4.2.1 Pharmacological Classes
    Potassium Channel Blocker [EPC]; Potassium Channel Antagonists [MoA]